### **A. Active Pharmaceutical Ingredients (APIs)** IOLCP is a dominant player in **generic APIs**, producing over **20 commercialized products**, with 8+ in development. The company specializes in high-volume, essential medicines across multiple therapeutic areas. #### **Key API Portfolio:** - **Ibuprofen & Derivatives**: Dex-Ibuprofen, Ibuprofen Sodium, Ibuprofen Lysinate - **Anti-Diabetic**: Metformin HCl (7,200 MTPA), Vildagliptin, Sitagliptin, Imeglimin - **Cardiovascular/Anti-Platelet**: Clopidogrel Bisulphate (Form-II, 240 MTPA), Losartan Potassium - **Gastrointestinal/Proton Pump Inhibitors**: Pantoprazole Sodium (>240 MTPA) - **Anti-Epileptic**: Levetiracetam, Lamotrigine (>200 MTPA), Gabapentin - **Anti-Cholesterol**: Fenofibrate - **NSAID/Analgesic**: Paracetamol (Total: 14,400 MTPA) #### **Therapeutic Segments Served:** - Anti-inflammatory - Analgesic & Antipyretic - Anti-diabetic - Cardiovascular - Anti-platelet - Anti-cholesterol - Proton Pump Inhibitor - Anti-convulsant - Anti-hypertensive #### **Regulatory Approvals & Submissions:** - **USFDA**: 16+ active Drug Master Files (DMFs), including Fenofibrate - **EDQM**: 19 Certificates of Suitability (CEPs) granted, covering Quetiapine, Mesalamine, Losartan, etc. - **ANVISA (Brazil)**: 10+ units audited and approved - **NMPA (China)**: Metformin HCl approved; China DMFs active for multiple APIs - **KFDA (South Korea), TFDA, WHO-GMP, EU-GMP**: Full compliance and approvals secured IOLCP leverages its approvals to strengthen access in regulated markets including the **U.S., Europe, Brazil, Russia, South Korea, and China**. --- ### **B. Specialty Chemicals** Established in **1996**, the Specialty Chemicals division supports both **captive API production** and **merchant sales**, serving diverse industries. #### **Key Product Portfolio & Capacities:** | Product | Capacity (MTPA) | Key Applications | |--------|------------------|------------------| | **Ethyl Acetate** | 100,000 | Pharmaceuticals, packaging, food, inks, adhesives | | **Iso Butyl Benzene (IBB)** | 12,000 | Key intermediate for Ibuprofen | | **Acetic Anhydride** | 25,000 | Paracetamol & Ibuprofen production; merchant sales | | **Mono Chloro Acetic Acid (MCA)** | 7,200 | Key intermediate; Asia’s first continuous dual-tech plant | | **Acetyl Chloride** | 5,200 | Key intermediate for APIs; green chemistry platform | #### **Strategic Differentiation:** - **REACH Certification** for Ethyl Acetate, Acetic Anhydride, and other products → enables **export to 40+ countries** - **Asia’s first continuous dual-technology (green chemistry) plant** for MCA and Acetyl Chloride - **Second-largest global producer of IBB** (~30% market share) - **Largest single-location Ethyl Acetate producer in India** --- ## **3. Market Position & Competitive Advantages** | Metric | Position | |-------|----------| | **Ibuprofen Global Market Share** | ~30–35% (World’s Largest Producer) | | **Global Ibuprofen Capacity** | >12,000 MTPA, 2 dedicated USFDA/EU-GMP units | | **Full Backward Integration** | **Only company globally** with complete control over KSMs & intermediates for Ibuprofen | | **Non-Ibuprofen API Revenue Share** | **34% (FY25)**, up from 18% in FY21; targeting **50:50 split** by FY26 | | **Export Revenue Share** | ~27% in FY25; **targeting 40–45%** in 2–3 years | | **API Sales to Regulated Markets** | ~40% of exports already; growing via CEP/DMF approvals | --- ## **4. Strategic Initiatives & Growth Drivers** ### **A. Product Diversification & Capacity Expansion** - **Paracetamol**: Commissioned **10,800 MTPA fully backward-integrated automated plant** (Unit-11), now exporting to **Europe and regulated markets** - **Clopidogrel**: Capacity increased by **33%** to meet rising cardiovascular demand - **Minoxidil**: Unit 9B under development, expected completion by **Q3 FY26** - **New APIs**: Expanding in antidiabetic, antiepileptic, and cardiovascular segments ### **B. Backward Integration & Vertical Control** IOLCP maintains **full backward integration** across: - **Ibuprofen**: All intermediates (e.g., IBB, 4-isobutylacetophenone), KSMs, and in-house acetic anhydride, PAP - **Paracetamol**: In-house production of **Para Amino Phenol (PAP)** and **Acetic Anhydride** - **Clopidogrel, Lamotrigine, Levetiracetam**: Backward integration on key intermediates completed (e.g., SABA HCl, 4-CBC) - **Metformin**: Actively reducing dependency on imported DCDA via government PLI support - **R&D Focus**: In-house development of key intermediates for **Gliflozins, Sartans, Edoxaban** ### **C. R&D & Innovation** - **DSIR-approved R&D facility** with **>120 specialists**, including 50+ scientists - **Annual R&D Spend**: ₹21.02 crore (~1.01% of revenue) - **Key Focus Areas**: - Generic API development (diabetes, heart disease, CNS) - Process innovation (continuous flow chemistry, green synthesis) - Biocatalysis (enzyme recycling in Sitagliptin process) - Waste reuse and green chemistry - **Recent Milestones**: - **Patents granted**: Sitagliptin process (2022), Edoxaban (2024) - **Breakthrough**: Recycled non-immobilized transaminase in Sitagliptin synthesis - **Scale-up Success**: 3 APIs commercialized; 2 at pilot scale (2024) ### **D. Sustainability & ESG Leadership** - **EcoVadis Silver Medal (2025)**: Top 15% globally in **environmental, social, and ethical performance** - **Zero Liquid Discharge (ZLD)** Effluent Treatment Plant - **17 MW captive co-generation plant** for energy self-reliance - **Sustainability Goals (2025–2035)**: - **Scope 1 Emissions**: 40% reduction by 2035 - **Scope 2**: Neutralization by 2026 - **Scope 3**: 40% reduction by 2035 - **95% renewable energy sourcing by 2030** - **Certifications**: ISO 9001, ISO 14001, BS OHSAS 18001 ### **E. Digital Transformation** - **R&D Tools**: SciFinder, Digital Lab Notebooks, DOE, ASPEN, Dynochem, AI/ML - **Manufacturing**: DCS-based automation across chemical and API units - **IT Platforms**: SAP HANA ERP, LIMS, CRM --- ## **5. Manufacturing Infrastructure** ### **Facilities Overview:** - **10 API units** in Barnala; all passed ANVISA audit - **Multi-product and dedicated plants** for Paracetamol, Metformin, Clopidogrel, Pantoprazole - **ISO Class-8 finishing zones**, isolators, vacuum drying, and micronization - **Solvent recovery systems** integrated across units - **Dedicated Chemical Division** plant with **8,600 kL storage**, automation, and high-purity handling ### **Production Technologies:** - **Batch Processing**: For APIs (SSRs: 60–75 kL total) - **Continuous Processing**: For intermediates and specialty chemicals - **Advanced Reactions**: Grignard, hydrogenation, cyanation, high-pressure reactions - **Proprietary Reactors**: Hastelloy, glass-lined, PTFE-lined